title: Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.
abstract: The term cholangiocarcinoma (CCA) comprises neoplasms of the intrahepatic, perihilar, and distal bile duct. Five-year survival rates of patients with CCA are below 20 %, and no targeted therapy could prove a benefit in comparison to the standard treatment of cisplatinum and gemcitabine. In recent years, next generation sequencing studies revealed a profound genomic heterogeneity of CCA subtypes potentially affecting the design of future therapy trials. This review provides a concise update on current clinical management of CCA including data of recent genomic studies and differences between CCA subtypes.
authors.affiliation: Department of Internal Medicine I, Johann Wolfgang Goethe-University Hospital, Frankfurt, Germany.
authors.forename: Dirk
authors.initials: D
authors.lastname: Walter
authors.affiliation: Johann Wolfgang Goethe-University Hospital, Dr. Senckenberg Institute of Pathology, Frankfurt, Germany.
authors.forename: Sylvia
authors.initials: S
authors.lastname: Hartmann
authors.affiliation: Department of Internal Medicine I, Johann Wolfgang Goethe-University Hospital, Frankfurt, Germany.
authors.forename: Oliver
authors.initials: O
authors.lastname: Waidmann
mesh_terms: D001650:Bile Duct Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D014408:Biomarkers, Tumor / Q000235:genetics*; D018281:Cholangiocarcinoma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D055088:Early Detection of Cancer / Q000379:methods*; D019317:Evidence-Based Medicine; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics; D005820:Genetic Testing / Q000379:methods*; D023281:Genomics / Q000639:trends; D006801:Humans; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D005819:Genetic Markers